Tower Research Capital (TRC)’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,455
| Closed | -$393K | – | 5636 |
|
|
2026
Q1 | $393K | Buy |
7,455
+5,844
| +363% | +$240K | 0.01% | 1099 |
|
|
2025
Q4 | $65.1K | Sell |
1,611
-701
| -30% | -$16.2K | ﹤0.01% | 2234 |
|
|
2025
Q3 | $17.4K | Sell |
2,312
-5,885
| -72% | -$37.6K | ﹤0.01% | 3431 |
|
|
2025
Q2 | $30.6K | Buy |
8,197
+1,274
| +18% | +$3.98K | ﹤0.01% | 3384 |
|
|
2025
Q1 | $19.1K | Buy |
6,923
+3,512
| +103% | +$14.3K | ﹤0.01% | 3016 |
|
|
2024
Q4 | $18.9K | Sell |
3,411
-2,706
| -44% | -$18.3K | ﹤0.01% | 3229 |
|
|
2024
Q3 | $51K | Sell |
6,117
-2,608
| -30% | -$21.5K | ﹤0.01% | 2709 |
|
|
2024
Q2 | $59.4K | Buy |
8,725
+8,106
| +1,310% | +$49.1K | ﹤0.01% | 2963 |
|
|
2024
Q1 | $4.06K | Sell |
619
-22,377
| -97% | -$146K | ﹤0.01% | 4745 |
|
|
2023
Q4 | $149K | Buy |
22,996
+21,942
| +2,082% | +$116K | ﹤0.01% | 2322 |
|
|
2023
Q3 | $5.3K | Sell |
1,054
-6,957
| -87% | -$44.1K | ﹤0.01% | 4738 |
|
|
2023
Q2 | $70.1K | Buy |
8,011
+4,361
| +119% | +$50.8K | ﹤0.01% | 2306 |
|
|
2023
Q1 | $43K | Sell |
3,650
-1,889
| -34% | -$18.1K | ﹤0.01% | 2642 |
|
|
2022
Q4 | $57K | Sell |
5,539
-1,062
| -16% | -$7.07K | ﹤0.01% | 2260 |
|
|
2022
Q3 | $39K | Sell |
6,601
-3,879
| -37% | -$14.4K | ﹤0.01% | 3387 |
|
|
2022
Q2 | $26K | Buy |
10,480
+6,924
| +195% | +$13.8K | ﹤0.01% | 3521 |
|
|
2022
Q1 | $11K | Buy |
3,556
+2,013
| +130% | +$8.59K | ﹤0.01% | 4216 |
|
|
2021
Q4 | $11K | Buy |
1,543
+784
| +103% | +$6.53K | ﹤0.01% | 4457 |
|
|
2021
Q3 | $8K | Sell |
759
-421
| -36% | -$4.37K | ﹤0.01% | 4569 |
|
|
2021
Q2 | $14K | Buy |
1,180
+566
| +92% | +$9.64K | ﹤0.01% | 4190 |
|
|
2021
Q1 | $14K | Buy |
+614
| New | +$13.5K | ﹤0.01% | 4168 |
|
Other funds holding TERN
Tower Research Capital (TRC)'s TERN Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 7,455 shares — an estimated $393K sold.
Tower Research Capital (TRC) first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $393K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,455 Terns Pharmaceuticals shares in Q2 2026, an estimated $393K.
- Tower Research Capital (TRC) first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- Tower Research Capital (TRC)'s Terns Pharmaceuticals position peaked at $393K in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.